MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme ROE Ratio 2011-2025 | EPZM
Annual ROE Ratio Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1213.85 | -125.31 | -51.43 | -53.06 | -57.06 | -54.64 | -78.08 | -34.32 | -3.34 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1213.85 | -125.31 | 84.07 |
Quarterly ROE Ratio Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -146.61 | -750.91 | -1178.96 | -1450.37 | -580.34 | -616.16 | -218.44 | -154.88 | -125.31 | -106.52 | -87.09 | -70.12 | -51.43 | -44.24 | -49.43 | -47.3 | -53.06 | -58.58 | -58.46 | -57.86 | -57.06 | -59.06 | -55.15 | -57.12 | -54.64 | -50.39 | -51.93 | -53.25 | -78.08 | -74.35 | -73.04 | -66.2 | -34.32 | -9.67 | -6.68 | -0.45 | -3.34 | -9.73 | -9.13 | -16.51 | -9.32 | -18.2 | -9.5 | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.45 | -1450.37 | -157.28 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
21.78 | $ 25.33 | -2.2 % | $ 1.23 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-68.71 | $ 4.71 | 0.86 % | $ 782 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-84.9 | $ 3.31 | -1.64 % | $ 256 M | USA |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-288.19 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-40.17 | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 210.45 | 0.14 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 1.3 | -2.26 % | $ 7.09 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.4 | -0.71 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 9.53 | 0.42 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-19.35 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.32 | 1.75 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | $ 89.4 | -0.99 % | $ 96.9 B | Britain |
 |
Baudax Bio
BXRX
|
242.53 | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
18.55 | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
16.2 | $ 570.03 | -1.89 % | $ 43.2 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-67.58 | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
94.87 | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
9.76 | $ 173.43 | 0.54 % | $ 25.3 B | USA |
 |
Cortexyme
CRTX
|
-36.89 | - | -1.05 % | $ 67.1 M | USA |
 |
BioVie
BIVI
|
-92.27 | $ 1.45 | -3.97 % | $ 2.14 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-55.55 | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 11.38 | -0.52 % | $ 736 M | USA |
 |
Benitec Biopharma
BNTC
|
-9.05 | $ 12.27 | -5.32 % | $ 505 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
338.32 | - | -5.68 % | $ 8.28 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 94.85 | -1.2 % | $ 27.2 B |  Germany |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 0.28 | -2.0 % | $ 609 M | Israel |
 |
Enochian Biosciences
ENOB
|
833.76 | - | - | $ 40.5 M | USA |
 |
Catalyst Biosciences
CBIO
|
540.06 | $ 14.5 | -5.29 % | $ 955 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Cerus Corporation
CERS
|
-37.26 | $ 2.13 | -0.7 % | $ 393 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 9.18 | 0.44 % | $ 1.5 B | Britain |